Business Wire

MA-PERKINELMER

Share
PerkinElmer Receives AOAC INTERNATIONAL First Action Official Methods of Analysis (OMA) Status for Solus One Salmonella Assay

PerkinElmer, Inc. , a global leader committed to innovating for a healthier world, today announced its Solus One™ Salmonella assay and methods have been granted First Action Official Methods of Analysis℠ (OMA) status, number 2020.03, from AOAC INTERNATIONAL (Association of Official Analytical Collaboration).

The Solus One Salmonella assay, which previously received ISO 16140 and AOAC Performance Tested Methods℠ (PTM) certification, detects Salmonella in select foods, with negative/presumptive positive results available in approximately 2 hours, post enrichment. Positive confirmation is then possible with an additional 24 hours. The assay can be run manually or with automation by adding Dynex Technologies’ DS-2® system.

Achieving OMA, the highest level of AOAC certification, involved a rigorous certification process that included simultaneous testing at over a dozen labs across the US, UK and South Africa. Data was then closely reviewed by an expert panel confirming result accuracy and repeatability of the Solus One Salmonella assay for a range of samples including raw salmon, romaine lettuce, cheddar cheese, instant non-fat dry milk, pasteurized liquid eggs, raw beef trim, cocoa, and herbs and spices. Tested food sample sizes ranged from 25g to 375g and swabs and sponges for production environment testing were also included.

“The World Health Organization estimates that Salmonella causes over 17 million people to become ill each year globally,” said Greg Sears, vice president and general manager, Food, PerkinElmer. “Members of the food industry, regulatory and research ecosystem around the world need to be able to depend on pathogen testing options that are reliable, consistent and efficient. We are pleased that our Solus One Salmonella assay and methods -- which have already been helping with food safety and quality globally -- have now achieved the highest level of AOAC certification.”

PerkinElmer’s pathogen assay offerings also include Solus One for Listeria and E. coli O157 and are part of the company’s broad food safety and quality solutions portfolio spanning across instruments, software, testing kits, reagents and services for grain, dairy, meats, produce, edible oils, seafood, herbs and spices and more. For more information please visit www.perkinelmer.com/category/food-safety-quality .

About PerkinElmer
PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Dubai Electricity and Water Authority PJSC Announces Record Breaking Revenue of AED 25 Billion and Operating Profit of AED 8.3 billion for the First Nine Months Ending Sept 202513.11.2025 11:19:00 CET | Press release

Dubai Electricity and Water Authority PJSC: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112162153/en/ HE Saeed Mohammed Al Tayer, MD & CEO of DEWA (Photo: AETOSWire) Record nine months of 2025 Results AED 24.9 billion AED 13.1 billion AED 8.3 billion AED 6.8 billion +5.9% YoY +11.9% YoY +21.5% YoY +24.8% YoY 9 months of 2025 Revenue 9 months of 2025 EBITDA 9 months of 2025 Operating Profit 9 months of 2025 Profit After Tax * figures are rounded Record Q3 2025 Results AED 10.3 billion AED 6.2 billion AED 4.6 billion AED 3.9 billion +4.5% YoY +20.4% YoY +29.8% YoY +35% YoY Q3, 2025 Revenue Q3, 2025 EBITDA Q3, 2025 Operating Profit Q3, 2025 Profit After Tax * figures are rounded Dubai Electricity and Water Authority PJSC (ISIN: AED001801011) (Symbol: DEWA), the Emirate of Dubai’s exclusive electricity and water services provider, which is listed on the Dubai Financial Market (DFM), today reported its consolidated financia

Quectel Unveils Advanced Matter over Thread Modules for Seamless Device Interoperability13.11.2025 10:00:00 CET | Press release

Quectel Wireless Solutions, an end-to-end global IoT solutions provider, today announced the launch of the KGM133S, the first in a range of Matter over Thread modules that provides innovative solutions for applications such as smart door locks, sensors, and lighting, helping the smart home industry overcome connectivity barriers and advance toward a new era of more efficient and seamless development. The KGM133S series modules are built based on the Silicon Labs EFR32MG24 chip, supporting the latest Matter 1.4 protocol. The modules are designed to enable seamless linkage of home devices across ecosystems, including Apple Home, Google Home, Amazon Alexa and Samsung SmartThings. “Protocol fragmentation remains one of the biggest obstacles to seamless smart device connectivity, and the Matter protocol is the key to overcoming it,” said Delbert Sun, Deputy General Manager at Quectel Wireless Solutions. “With our new Matter over Thread modules, we are helping the industry achieve true inter

SBC Medical Group Announces Commencement of Tender Offer for Shares of Waqoo, Inc.13.11.2025 09:57:00 CET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that on November 13, 2025, SBC Medical Group Co., Ltd. (the “Tender Offeror”) has resolved to acquire shares of common stock of Waqoo, Inc. (Securities Code: 4937, listed on the Tokyo Stock Exchange Growth Market; the “Target Company”) through a tender offer (the “Tender Offer”) pursuant to the Financial Instruments and Exchange Act of Japan (Act No. 25 of 1948, as amended; the “FIEA”), as described below. The Tender Offeror is a Japanese subsidiary ultimately owned by SBC Medical Group Holdings Incorporated (“SBCHD”), a U.S. corporation listed on NASDAQ and engaged in management support services for medical clinics both domestically and internationally. As of today, the Tender Offeror holds 353,600 shares of the Target Company’s common stock (ownership ratio: 9.49%).

IQM Launches Halocene, a New Quantum Computer Product Line for Error Correction13.11.2025 09:56:00 CET | Press release

IQM Halocene is a new quantum computer product line aimed at error correction development. It will start with a150-qubit system to be delivered by the end of 2026 and extend all the way to 1,000-qubits. The new product line is based on an open and modular error correction stack, which will allow end-users to experiment and run different quantum error correction features. IQM’s goal is to enable users from supercomputing centers, research organizations, and universities to innovate on quantum error correction research with an open platform. IQM has sold more on-premises quantum systems globally than any other manufacturer, and the company expects the new Halocene product line to accelerate its revenue growth further IQM Quantum Computers, a global leader in superconducting quantum computers, today announced the launch of its new product line called IQM Halocene. The new product line is based on open and modular on-premises quantum computers designed for quantum error correction research

JSR Life Sciences Enters Definitive Agreement to Transfer Crown Bioscience to Adicon Holdings Limited13.11.2025 09:45:00 CET | Press release

Strategic Transaction Positions Crown Bioscience for Accelerated Growth in Translational Oncology JSR Life Sciences LLC ("JSR Life Sciences"), a global leader in life sciences materials and services, today announced it has entered into a definitive agreement to transfer Crown Bioscience Inc. ("Crown Bioscience") to Adicon Holdings Limited ("Adicon"), a premier independent clinical laboratory provider in China and a portfolio company of The Carlyle Group. The transaction, subject to customary closing conditions, is expected to close in 2026. This strategic move will enable Crown Bioscience to operate as a standalone entity under Adicon's ownership. Crown Bioscience's comprehensive portfolio of translational oncology services, including its world-leading patient-derived xenograft (PDX) models, tumor organoid platforms, immuno-oncology assays, and bioinformatics solutions, will transition to Adicon, positioning the company to accelerate advancements in precision medicine and drug discover

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye